Burning Rock's CEO Yusheng Han purchased 73,141 ADSs, totaling 145,874 shares bought recently, reflecting confidence in the company.
Quiver AI Summary
Burning Rock Biotech Limited announced that its founder and CEO, Mr. Yusheng Han, has purchased 73,141 American Depositary Shares (ADSs) for approximately $618,218 from the open market, aligning with insider trading regulations. This recent acquisition adds to a total of 145,874 ADSs purchased over three consecutive post-earnings trading windows, amounting to around $1.98 million, reflecting Mr. Han's confidence in the company's prospects. He may continue to buy more ADSs depending on market conditions and compliance with securities regulations. Burning Rock specializes in next generation sequencing technology for precision oncology, focusing on therapy selection testing and cancer early detection.
Potential Positives
- Mr. Yusheng Han's purchase of 73,141 ADSs signals strong insider confidence in the company, which may positively influence investor sentiment.
- The total acquisition of 145,874 ADSs across multiple trading windows demonstrates Mr. Han's commitment and belief in the company's future prospects and performance.
- The company's focus on next-generation sequencing technology in precision oncology highlights its potential for growth in a significant and evolving healthcare sector.
Potential Negatives
- The press release highlights insider buying, which could indicate a lack of investor confidence if the overall stock performance is weak.
- The repetitive nature of insider purchases in the post-earnings trading windows may raise concerns among investors about potential stock price manipulation.
- Despite the reported confidence from the CEO, the company does not provide detailed information regarding financial performance or future projections, which may lead to uncertainty among investors.
FAQ
Who is the CEO of Burning Rock Biotech Limited?
The CEO of Burning Rock Biotech Limited is Mr. Yusheng Han, who is also the founder and chairman.
What recent investment did Mr. Yusheng Han make?
Mr. Yusheng Han purchased 73,141 ADSs of Burning Rock for US$618,217.72 from the open market.
How many ADSs has Mr. Han purchased in total?
In total, Mr. Han has purchased 145,874 ADSs for US$1,976,542.90 across three post-earnings trading windows.
What is the focus of Burning Rock Biotech Limited?
Burning Rock focuses on next generation sequencing technology in the field of precision oncology, including cancer detection and therapy selection.
Where can I find more information about Burning Rock?
More information about Burning Rock can be found on their investor relations website: ir.brbiotech.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BNR Insider Trading Activity
$BNR insiders have traded $BNR stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BNR stock by insiders over the last 6 months:
- YUSHENG HAN purchased 314,870 shares for an estimated $5,466,143
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BNR Hedge Fund Activity
We have seen 5 institutional investors add shares of $BNR stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KYNAM CAPITAL MANAGEMENT, LP added 232,672 shares (+23.4%) to their portfolio in Q1 2026, for an estimated $3,752,999
- CRCM LP removed 209,329 shares (-42.6%) from their portfolio in Q1 2026, for an estimated $3,376,476
- PROSPERA FINANCIAL SERVICES INC removed 31,185 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $503,014
- CITADEL ADVISORS LLC added 17,669 shares (+inf%) to their portfolio in Q1 2026, for an estimated $285,000
- MARSHALL WACE, LLP removed 10,903 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $175,865
- RENAISSANCE TECHNOLOGIES LLC added 4,290 shares (+13.8%) to their portfolio in Q1 2026, for an estimated $69,197
- MORGAN STANLEY added 3,432 shares (+29.0%) to their portfolio in Q1 2026, for an estimated $55,358
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 73,141 of the Company’s ADSs for US$618,217.72 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company’s insider trading policy. As of the date of this press release, combined with 72,733 ADSs purchased in the last two post-earnings trading windows, Mr. Han has purchased an aggregate of 145,874 of the Company’s ADSs for US$1,976,542.90 across three consecutive post-earnings trading windows, indicating his confidence in the Company’s business and prospect.
Mr. Han may continue to purchase the Company’s ADSs through open-market transactions, privately negotiated transactions or block trades, or other legally permissible means, depending on market conditions and in accordance with the applicable rules and regulations. The timing and conditions of Mr. Han’s purchase will be subject to various factors, including the requirements under Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934, as well as the Company’s insider trading policy.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: ir.brbiotech.com.
Contact: [email protected]
